ALGS - Aligos Therapeutics, Inc.

5.45
-0.380   -6.972%

Share volume: 124,251
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$5.83
-0.38
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 16%
Liquidity 58%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.68%
1 Month
-40.24%
3 Months
-77.99%
6 Months
-38.56%
1 Year
642.71%
2 Year
369.83%
Key data
Stock price
$5.45
P/E Ratio 
0.00
DAY RANGE
$5.38 - $6.00
EPS 
-$16.37
52 WEEK RANGE
$0.35 - $46.80
52 WEEK CHANGE
$642.71
MARKET CAP 
142.942 M
YIELD 
N/A
SHARES OUTSTANDING 
76.810 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
-0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$126,715
AVERAGE 30 VOLUME 
$191,330
Company detail
CEO: Lawrence M. Blatt
Region: US
Website: www.aligos.com
Employees: 90
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)

Recent news
loading